Local paclitaxel delivery as a treatment of persistent, recurrent in-stent restenosis - Safety assessment

Kardiologia Polska

Volumn 64, Issue 3, 2006, Pages 268-272

  Buszman, Paweł ^a   Zurakowski, Aleksander ^a,b   Gruszka, Agata ^a   Szkróbka, Iwona ^a   Peszek Przybyła, Ewa ^a   Radwan, Kazimierz ^a   Milewski, Krzysztof ^a   Barteczko, Zenon ^a   Tendera, Michał ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b l skiego Uniwersytetu Medycznego w Katowicach Górno l skie Centrum Medyczne   (Poland)

Author keywords

In stent restenosis; Local intramural drug delivery; Paclitaxel

Indexed keywords

CYTOTOXIC AGENT; PACLITAXEL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BALLOON CATHETER; CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RECURRENT DISEASE; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 33747333640     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-95.
3. Moses JW, Leon MB, Popma JJ, et al. N Sirolismus-eluting stents versus standard stents in patients with stenosis in native coronary artery. N Engl J Med 2003;349:1315-1323 -
4. Stone NG, Ellis SG, Cox DA i wsp. A polymer-based paclitaxel-eluting stent in patient with coronary artery disease. N Engl J Med 2004; 350: 221-31.
5. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344:250-6.
6. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-71.
7. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537-45.
8. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109: 487-93.
9. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-4.
10. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000; 35: 1969-76.
11. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003; 24: 1462-7.
12. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000; 86: 879-84.
13. Buszman P, Kiesz S, Gaszewska E, et al. Miejscowe śró dścienne podawanie heparyny niskocza̧steczkowej w trakcie zabiegu implantacji stentu wieńcowego. Ocena bezpieczeństwa metody. Kardiol Pol 1998; 48: 227-31.
14. Kiesz S, Buszman P, Martin JL, et al. Local delivery of enoxaparin to decrease restenosis after stenting: result of initial multicenter trial. Circulation 2001; 103: 26-31.